Clinical Trials Logo

Clinical Trial Summary

NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).


Clinical Trial Description

After someone has a MI, their heart 'remodels', which means that it changes in size and shape. This damage can lead to it being weaker and less efficient, and ultimately to major heart problems. There are some drugs currently available which help prevent remodelling and are used for treatment post-MI. However, there is still a high rate of remodelling and major heart problems in people post-MI. NP202 works in a different way to the drugs that are currently approved, and has been shown in animal studies to prevent post-MI remodelling.

This study will assess NP202 versus placebo on remodelling over a 3 month treatment period, with 1 month follow up ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02557217
Study type Interventional
Source Armaron Bio Pty Ltd
Contact Grant McLachlan
Phone +61 3 9652 2117
Email grant.mclachlan@armaronbio.com
Status Recruiting
Phase Phase 2
Start date October 2015
Completion date February 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05601999 - Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction Phase 3
Recruiting NCT06147986 - Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients Phase 2
Not yet recruiting NCT05881382 - Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction Phase 3
Enrolling by invitation NCT02615015 - SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls N/A
Recruiting NCT05812963 - IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT05450757 - Shanghai ST-segment Elevation Myocardial Infarction Cohort
Active, not recruiting NCT03278509 - Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Phase 4
Not yet recruiting NCT03263468 - Revascularization StrategIes for ST Elevation Myocardial Infarction Trial N/A
Not yet recruiting NCT03266328 - Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University N/A
Completed NCT03156699 - The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Enrolling by invitation NCT04970238 - Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Phase 4
Recruiting NCT02224534 - Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Phase 4
Completed NCT01136187 - Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Not yet recruiting NCT04063345 - Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction Phase 2/Phase 3
Active, not recruiting NCT03646357 - BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function Phase 4
Completed NCT03984071 - The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Completed NCT03740776 - The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
Completed NCT03435133 - Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI N/A